[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604830":3},{"organization":4,"outcomesModule":7,"designInfo":101,"detailedDescription":100,"studyPopulation":104,"armGroups":105,"interventions":116,"overallOfficials":121,"centralContacts":125,"locations":131,"responsibleParty":149,"collaborators":100,"id":151,"slug":152,"hasResults":153,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":100,"eligibilityCriteria":156,"healthyVolunteers":157,"sex":158,"minAge":159,"maxAge":100,"enrollmentInfo":160,"targetDuration":100,"studyType":163,"phases":100,"briefSummary":164,"conditions":165,"keywords":100,"overallStatus":133,"whyStopped":100,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":176},{"fullName":5,"class":6},"University of Minnesota","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":100,"otherOutcomes":100},[9,13,16,19,22,25,28,30,32,34,36,38,40,42,44,46,48,50,52,54,56,58,60,62,64,66,68,70,72,74,76,78,80,82,84,86,88,90,92,94,96,98],{"measure":10,"description":11,"timeFrame":12},"EliSpot - Day 1","Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes","Day 1",{"measure":14,"description":11,"timeFrame":15},"EliSpot - Day 4","Day 4",{"measure":17,"description":11,"timeFrame":18},"EliSpot - Day 7","Day 7",{"measure":20,"description":11,"timeFrame":21},"EliSpot - Day 14","Day 14",{"measure":23,"description":11,"timeFrame":24},"EliSpot - Day 21","Day 21",{"measure":26,"description":11,"timeFrame":27},"EliSpot - Day 28","Day 28",{"measure":29,"description":11,"timeFrame":12},"Ex Vivo TNF Production - Day 1",{"measure":31,"description":11,"timeFrame":15},"Ex Vivo TNF Production - Day 4",{"measure":33,"description":11,"timeFrame":18},"Ex Vivo TNF Production - Day 7",{"measure":35,"description":11,"timeFrame":21},"Ex Vivo TNF Production - Day 14",{"measure":37,"description":11,"timeFrame":24},"Ex Vivo TNF Production - Day 21",{"measure":39,"description":11,"timeFrame":27},"Ex Vivo TNF Production - Day 28",{"measure":41,"description":11,"timeFrame":12},"Flow Cytometry of Peripheral Blood Leukocytes - Day 1",{"measure":43,"description":11,"timeFrame":15},"Flow Cytometry of Peripheral Blood Leukocytes - Day 4",{"measure":45,"description":11,"timeFrame":18},"Flow Cytometry of Peripheral Blood Leukocytes - Day 7",{"measure":47,"description":11,"timeFrame":21},"Flow Cytometry of Peripheral Blood Leukocytes - Day 14",{"measure":49,"description":11,"timeFrame":24},"Flow Cytometry of Peripheral Blood Leukocytes - Day 21",{"measure":51,"description":11,"timeFrame":27},"Flow Cytometry of Peripheral Blood Leukocytes - Day 28",{"measure":53,"description":11,"timeFrame":12},"Quantification of Cytokines in Serum - Day 1",{"measure":55,"description":11,"timeFrame":15},"Quantification of Cytokines in Serum - Day 4",{"measure":57,"description":11,"timeFrame":18},"Quantification of Cytokines in Serum - Day 7",{"measure":59,"description":11,"timeFrame":21},"Quantification of Cytokines in Serum - Day 14",{"measure":61,"description":11,"timeFrame":24},"Quantification of Cytokines in Serum - Day 21",{"measure":63,"description":11,"timeFrame":27},"Quantification of Cytokines in Serum - Day 28",{"measure":65,"description":11,"timeFrame":12},"Quantification of Chemokines in Serum - Day 1",{"measure":67,"description":11,"timeFrame":15},"Quantification of Chemokines in Serum - Day 4",{"measure":69,"description":11,"timeFrame":18},"Quantification of Chemokines in Serum - Day 7",{"measure":71,"description":11,"timeFrame":21},"Quantification of Chemokines in Serum - Day 14",{"measure":73,"description":11,"timeFrame":24},"Quantification of Chemokines in Serum - Day 21",{"measure":75,"description":11,"timeFrame":27},"Quantification of Chemokines in Serum - Day 28",{"measure":77,"description":11,"timeFrame":12},"Transcriptional Profiling - Day 1",{"measure":79,"description":11,"timeFrame":15},"Transcriptional Profiling - Day 4",{"measure":81,"description":11,"timeFrame":18},"Transcriptional Profiling - Day 7",{"measure":83,"description":11,"timeFrame":21},"Transcriptional Profiling - Day 14",{"measure":85,"description":11,"timeFrame":24},"Transcriptional Profiling - Day 21",{"measure":87,"description":11,"timeFrame":27},"Transcriptional Profiling - Day 28",{"measure":89,"description":11,"timeFrame":12},"CBC - Day 1",{"measure":91,"description":11,"timeFrame":15},"CBC - Day 4",{"measure":93,"description":11,"timeFrame":18},"CBC - Day 7",{"measure":95,"description":11,"timeFrame":21},"CBC - Day 14",{"measure":97,"description":11,"timeFrame":24},"CBC - Day 21",{"measure":99,"description":11,"timeFrame":27},"CBC - Day 28",null,{"allocation":100,"interventionModel":100,"interventionModelDescription":100,"primaryPurpose":100,"observationalModel":102,"timePerspective":103,"maskingInfo":100},"CASE_CONTROL","PROSPECTIVE","Patients with and without sepsis in the ICU, compared to healthy volunteers",[106,110,113],{"label":107,"type":100,"description":100,"interventionNames":108},"ICU Patients with Sepsis",[109],"Other: Observational Only",{"label":111,"type":100,"description":100,"interventionNames":112},"ICU Patients without Sepsis",[109],{"label":114,"type":100,"description":100,"interventionNames":115},"Healthy Volunteers",[109],[117],{"type":6,"name":118,"description":119,"armGroupLabels":120,"otherNames":100},"Observational Only","No intervention is included in this study",[114,107,111],[122],{"name":123,"affiliation":5,"role":124},"Thomas Griffith, PhD","PRINCIPAL_INVESTIGATOR",[126],{"name":127,"role":128,"phone":129,"phoneExt":100,"email":130},"Mrunmayi Tilak","CONTACT","612-624-9990","mtilak@umn.edu",[132],{"facility":5,"status":133,"city":134,"state":135,"zip":136,"country":137,"countryCode":138,"cosmosGeoPoint":139,"geoPoint":144,"contacts":145},"RECRUITING","Minneapolis","Minnesota","55455","United States","US",{"type":140,"coordinates":141},"Point",[142,143],-93.26384,44.97997,{"lat":143,"lon":142},[146],{"name":147,"role":128,"phone":100,"phoneExt":100,"email":148},"Kristine Kancans","kanca008@umn.edu",{"type":150,"investigatorFullName":100,"investigatorTitle":100,"investigatorAffiliation":100,"oldNameTitle":100,"oldOrganization":100},"SPONSOR","100604830","assessing-immune-dysfunction-in-sepsis-100604830",false,"NCT07154615","Assessing Immune Dysfunction in Sepsis","ICU With Sepsis Inclusion Criteria:\n\n* Age ≥ 18\n* Presumed diagnosis of sepsis, defined as \"patients with life-threatening organ dysfunction caused by a dysregulated host response to infection\"\n* Patients in the ICU who meet 2 or more of the quick SOFA (qSOFA) definition along with organ dysfunction:\n\n  1. Respiration rate ≥ 22 breaths\u002Fmin and\u002For mechanically ventilated\n  2. An alteration in mental status\n  3. Systolic blood pressure of less than 100 mm Hg and\u002For receiving inotropes to maintain blood pressure AND\u002FOR\n\n  \u003C!-- -->\n\n  1. An acute change in SOFA score ≥2 points, consequent to the infection (can assume SOFA score = 0 in patients with no pre-existing organ dysfunction)\n\nICU Without Sepsis Inclusion Criteria:\n\n* Age ≥ 18\n* Patients requiring care at a M Health Fairview ICU due to high acuity of illness and no other evidence of sepsis\n\nHealthy Volunteer Inclusion Criteria\n\n* Age greater or equal to 18\n* ASA status 1, 2 or 3\n* May include patients who are receiving dialysis in an outpatient setting\n\nExclusion Criteria (all groups):\n\n* Active cancer with chemotherapy and\u002For radiation treatment within the past 6 weeks\n* Medication usage that includes immunosuppressive drugs, biologic agents, cytokines, growth factor and interleukins\n* Steroid medication usage of \\> 300mg hydrocortisone per day (equivalent of \\> 20mg prednisone). Patients with chronic steroid use will be excluded, however patients who have had stress dose steroids administered following admission will be included.\n* Patients with a history of, or who currently have evidence of autoimmune disease, including but not limited to: myasthenia gravis, Guillain Barré syndrome, systemic lupus erythematosus, multiple sclerosis, scleroderma, ulcerative colitis, Crohn's disease, autoimmune hepatitis, Wegener's granulomatosis, HIV\u002FAIDS, etc.\n* Patients with active or a history of acute or chronic lymphocytic leukemia\n* Known history of chronic hepatitis B (HBV) infection and not on treatment with HBV nucleoside analogues prior to the current hospitalization, or HBV DNA \\> 100 IU\u002FmL\n* Known history of infection with hepatitis C (HCV) and currently undergoing treatment for HCV infection or has detectable HCV RNA\n* Participation in another investigational interventional drug study within the past 4 weeks\n* Current pregnancy\n* Current incarceration",true,"ALL","18 Years",{"count":161,"type":162},150,"ESTIMATED","OBSERVATIONAL","Sepsis leads to sustained immune system dysfunction resulting in increased susceptibility to secondary infection while in the hospital or after discharge. Consequently, many of the \\~2 million Americans that develop sepsis every year will end up back in the ICU, weeks and months later. The objective of this study is to define the cellular and molecular mechanisms driving the dysfunction and reprogramming of T cells and B cells that mediate cellular and humoral immunity using a combination of phenotypic, functional, genomic, and metabolomic assays.",[166],"Sepsis","2026-09-21",{"date":169,"type":170},"2026-09-23","ACTUAL",{"date":172,"type":170},"2026-03-01",{"date":174,"type":162},"2028-11-01",{"name":5,"class":6},1]